Advertisement

Search Results

Advertisement



Your search for The ASCO Post matches 222 pages

Showing 151 - 200


gynecologic cancers

FDA Grants Breakthrough Therapy Designation to Rucaparib in Advanced Ovarian Cancer With BRCA Mutations

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Clovis Oncology’s investigational agent rucaparib as monotherapy treatment of advanced ovarian cancer in patients who have received at least two lines of prior platinum-containing therapy, with...

gynecologic cancers
gynecologic cancers

Experimental Immunotherapy Delays Recurrence for Stage III and IV Ovarian Cancers

According to a phase II study presented at the Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, an experimental immunotherapy is in the works that can target an individual woman’s ovarian tumor and extend the time period between initial treatment and the cancer’s...

gynecologic cancers
issues in oncology

Sentinel Lymph Node Mapping Identifies Positive Lymph Nodes in Women With High-Risk Endometrial Cancer

In a study of women with high-grade endometrial cancer, researchers at The University of Texas MD Anderson Cancer Center found sentinel lymph node mapping accurately identified all women with node-positive, high-risk endometrial cancer, when prospectively compared to a complete pelvic and...

gynecologic cancers
gynecologic cancers

Addition of Bevacizumab to Chemotherapy Extends Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer

In a phase III study of women with ovarian cancer, researchers found that the addition of bevacizumab (Avastin) to standard chemotherapy extended median overall survival by 5 months compared to standard chemotherapy alone. The bevacizumab combination was also associated with a significant...

gynecologic cancers

New Surgical Algorithm Results in Improved Complete Resection Rates in Advanced Ovarian Cancer

A surgical algorithm developed and implemented by ovarian cancer specialists at The University of Texas MD Anderson Cancer Center dramatically increases the frequency of complete removal of all visible tumor—a milestone strongly tied to improved chances of survival. The researchers describe...

gynecologic cancers

Human Reovirus Formulation Receives FDA Orphan Drug Designation for Fallopian Tube Cancer

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for Oncolytics Biotech’s proprietary formulation of the human reovirus (Reolysin) for the treatment of fallopian tube cancer. The designation was granted on the basis of the company's December 2014 application for ...

gynecologic cancers

12-Year Study Suggests Procedures to Prevent Cervical Cancer Do Not Affect Fertility

Common surgical procedures used to diagnose and treat precancerous cervical lesions do not decrease women's chances of becoming pregnant, according to a study conducted by Kaiser Permanente Northwest, which followed nearly 100,000 women for up to 12 years. In fact, researchers found that women ...

gynecologic cancers
issues in oncology

Nutrient-Wide Association Study Shows Increased Coffee Intake May Be Associated With Lower Risk of Endometrial Cancer

Women who drank about four cups of coffee per day appeared to have decreased endometrial cancer risk compared with those who drank less than a cup each day, according to a study published by Merritt et al in Cancer Epidemiology, Biomarkers & Prevention. A New Approach “We used a...

gynecologic cancers

FDA Grants Orphan Drug Designation to Human Reovirus Formulation for the Treatment of Ovarian Cancer

Oncolytics Biotech, Inc, a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for its proprietary formulation of the human reovirus...

gynecologic cancers
issues in oncology

Researchers Pinpoint Two Genes That Trigger Most Severe Form of Ovarian Cancer

Researchers at University of North Carolina School of Medicine have created the first mouse model of the most aggressive form of ovarian cancer and found a potential route to better treatments and much-needed diagnostic screens. Led by Terry Magnuson, PhD, the Sarah Graham Kenan Professor and Chair ...

issues in oncology
breast cancer
gynecologic cancers
issues in oncology

Next-Generation Sequencing Uncovers Potential Genetic Drivers of Rare Breast Tumors

A new study from researchers at the University of Michigan Comprehensive Cancer Center characterizes the genetic underpinnings of phyllodes tumors, a rare type of breast tumor. The study offers the first comprehensive analysis of the molecular alterations at work in these tumors, according to Cani...

gynecologic cancers

Bisphosphonates May Help Prevent Endometrial Cancer

A new analysis suggests that women who use bisphosphonates have about half the risk of developing endometrial cancer as women who do not use the drugs. The findings by Alford et al, published early online in Cancer, supports other research that has shown an anticancer effect of this type of...

gynecologic cancers

FDA Approves Companion Diagnostic for the Detection of BRCA1/2 Mutations in Ovarian Cancer

Today’s approval by the U.S. Food and Drug Administration (FDA) of olaparib (Lynparza) occurred concurrently with that of a companion diagnostic, BRACAnalysis CDx. This genetic test is designed to detect the presence of mutations in the BRCA genes in blood samples from patients with ovarian...

gynecologic cancers

FDA Approves Olaparib to Treat BRCA-Mutated Advanced Ovarian Cancer

The U.S. Food and Drug Administration (FDA) today granted accelerated approval to olaparib (Lynparza) for women with advanced ovarian cancer with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer, as detected by an FDA-approved test, who have been treated with three ...

gynecologic cancers

FDA Warns Against Using Laparoscopic Power Morcellators to Treat Uterine Fibroids

The U.S. Food and Drug Administration (FDA) today announced that it is taking immediate steps to help reduce the risk of spreading unsuspected cancer in women being treated for uterine fibroids. In an updated safety communication, originally issued in April 2014, the FDA warned against using...

issues in oncology
gynecologic cancers

Researchers Identify Biomarker of Response to New Ovarian Cancer Drug

Researchers have found a way to identify which ovarian cancer patients are likely to respond well to a new anticancer drug called rucaparib. Previous clinical trials have shown that women with platinum-sensitive tumors with BRCA1/2 mutations respond well to rucaparib. In new findings presented...

gynecologic cancers
gynecologic cancers

FDA Approves Bevacizumab Plus Chemotherapy for Platinum-Resistant, Recurrent Ovarian Cancer

The U.S. Food and Drug Administration (FDA) approved bevacizumab (Avastin) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for the treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. AURELIA Trial ...

gynecologic cancers
issues in oncology

HPV Vaccine Uptake Among Girls Is Lowest in States With Highest Rates of Cervical Cancer

The proportion of adolescent girls receiving human papillomavirus (HPV) vaccines was much lower in states with higher rates of cervical cancer incidence and mortality, according to data presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health...

gynecologic cancers
gynecologic cancers
issues in oncology

CDC Reports That Millions of U.S. Women Are Not Getting Screened for Cervical Cancer

Despite evidence that cervical cancer screening saves lives, about 8 million women aged 21 to 65 years have not been screened for cervical cancer in the past 5 years, according to a new report from the Centers for Disease Control and Prevention (CDC) published in Morbidity and Mortality Weekly ...

gynecologic cancers
gynecologic cancers
issues in oncology
supportive care
issues in oncology

Single-Day Education Program Mitigates Psychosexual Side Effects of Risk-Reducing Salpingo-Oophorectomy

More women are undergoing salpingo-oophorectomy as a cancer prevention measure, but many are unaware of the potential sexual or psychological side effects of the procedure. A new study by researchers at Dana-Farber Cancer Institute demonstrated that a half-day educational program can help ...

gynecologic cancers
gynecologic cancers

ESMO 2014: Adding Cediranib to Chemotherapy Improves Progression-Free Survival in Metastatic or Recurrent Cervical Cancer

For patients with recurrent or metastatic cervical cancer, adding the experimental drug cediranib to standard chemotherapy improved tumor shrinkage and resulted in a modest improvement in progression-free survival, researchers reported at the ESMO 2014 Congress in Madrid (Abstract LBA25_PR). In...

cns cancers
lung cancer
gynecologic cancers

Aldoxorubicin Receives FDA Orphan Drug Designations for Glioblastoma, Small Cell Lung Cancer, and Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designations to aldoxorubicin in three indications: glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and...

gynecologic cancers

Radiation Therapy With Concurrent Chemotherapy After Surgery Is an Effective Treatment for High-Risk Endometrial Cancer

Radiation therapy with concurrent paclitaxel chemotherapy following surgery is an effective treatment for high-risk endometrial cancer, according to a study reported by Cho et al in the International Journal of Radiation Oncology • Biology • Physics   Endometrial...

gynecologic cancers

FDA Approves Bevacizumab for Aggressive and Late-Stage Cervical Cancer

The U.S. Food and Drug Administration (FDA) has approved the antiangiogenic agent bevacizumab (Avastin) for the treatment of persistent, recurrent, or metastatic cervical cancer. The new indication is approved for use in combination with paclitaxel and cisplatin or paclitaxel and topotecan. The FDA ...

issues in oncology
gynecologic cancers

Researchers Identify Priority Targets for Immunotherapy in Epithelial Ovarian Cancer

Researchers at Roswell Park Cancer Institute (RPCI) have found that the expression pattern of a unique class of tumor-associated antigens, known as the MAGE cancer-testis antigens (CTAs), correlates with clinical outcome in epithelial ovarian cancer. Based on their findings, the researchers have...

gynecologic cancers

FDA Grants Bevacizumab Priority Review for Recurrent Platinum-Resistant Ovarian Cancer

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application and granted Priority Review for bevacizumab (Avastin) plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer. “The majority of women...

gynecologic cancers
issues in oncology

Negative HPV Screening Test Result Is a Better Predictor of Cervical Cancer Risk Than a Negative Pap Test Result

A study by investigators at the National Cancer Institute of more than 1 million women has found that a negative test for human papillomavirus (HPV) infection is a more reliable predictor of the risk of developing cervical cancer than a negative Pap test. The findings suggest that primary HPV...

gynecologic cancers

FDA Grants Bevacizumab Priority Review for Certain Types of Cervical Cancer

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application and granted Priority Review for bevacizumab (Avastin) plus chemotherapy in the treatment of women with persistent, recurrent, or metastatic cervical cancer.  The designation...

gynecologic cancers

FDA Advisory Committee Votes Against Accelerated Approval for Olaparib in Ovarian Cancer

The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 that current evidence from clinical studies does not support an accelerated approval for use of olaparib as a maintenance treatment for women with platinum-sensitive relapsed ovarian cancer who have...

gynecologic cancers

ASCO 2014: Cediranib Plus Olaparib Significantly Increases Progression-Free Survival in Women With Recurrent Ovarian Cancer

The combination of two investigational oral drugs, the PARP inhibitor olaparib and the antiangiogenic drug cediranib, significantly extended progression-free survival and increased the overall response rate compared to olaparib alone in a phase II study among women with recurrent,...

breast cancer
gynecologic cancers
issues in oncology
issues in oncology
issues in oncology

ASCO 2014: Women With BRCA Mutations Report Significant Side Effects Following Risk-Reducing Salpingo-Oophorectomy

The majority of women with BRCA1 and BRCA2 mutations experience sexual dysfunction, menopausal symptoms, cognitive and stress issues, and poor sleep following risk-reducing salpingo-oophorectomy, according to results of a new study from the Abramson Cancer Center and the Perelman School of Medicine ...

gynecologic cancers
issues in oncology

U.S. Cervical Cancer Rates Higher Than Previously Reported, Particularly Among Older Women and African American Women

Cervical cancer rates in the United States are higher than previously believed, particularly among 65- to 69-year-old women and African American women, according to a study by Rositch et al published in Cancer. Current U.S. cervical cancer screening guidelines do not recommend routine Pap smears...

gynecologic cancers

Glutamine Ratio Is Key Indicator of Tumor Aggression in Ovarian Cancer, Study Finds

An analysis of the metabolic profiles of hundreds of ovarian tumors has revealed a new test to determine whether ovarian cancer cells have the potential to metastasize. The study, which was published in Molecular Systems Biology, also suggests how ovarian cancer treatments can be tailored based on...

gynecologic cancers

ASTRO Issues Guideline on the Role of Postoperative Radiation Therapy for Endometrial Cancer

The American Society for Radiation Oncology (ASTRO) has issued a new guideline, “The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline,” that details the use of adjuvant radiation therapy in the treatment of endometrial cancer. The...

gynecologic cancers
issues in oncology

FDA Approves First HPV Test for Primary Cervical Cancer Screening

The U.S. Food and Drug Administration (FDA) today approved the first human papillomavirus (HPV) DNA test that can be used as a primary cervical cancer screening test for women aged 25 years and older. The test also can provide information about the patient’s risk for developing cervical...

gynecologic cancers

FDA Discourages Use of Laparoscopic Power Morcellation for Removal of Uterus or Uterine Fibroids

In a safety communication notice issued yesterday, the U.S. Food and Drug Administration (FDA) discouraged the use of laparoscopic power morcellation for the removal of the uterus (hysterectomy) or uterine fibroids (myomectomy) in women because, based on an analysis of currently available data, it...

gynecologic cancers
issues in oncology

PARP Inhibitor Veliparib Might Benefit Women With Resistant Gynecologic Cancers and BRCA Mutation

Preliminary research suggests that a targeted oral agent may improve outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies. According to a phase II study presented at the Society of Gynecologic...

gynecologic cancers
gynecologic cancers

Women With Gynecologic Cancers May Live Longer When Treated at High-Volume Medical Centers

Women with ovarian and other gynecologic cancers live significantly longer when they receive care at hospitals that treat a large number of patients with these conditions, according to research on more than 850,000 women. The findings, based on information from the nation’s largest cancer...

gynecologic cancers
issues in oncology

Women With BRCA1 Mutations May Still Be at Risk for Rare Types of Uterine Cancer After Preventive Salpingo-Oophrectomy

Women with BRCA1 mutations may have an increased risk for developing rare types of aggressive uterine cancer despite having their ovaries and fallopian tubes removed, suggest preliminary findings presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer held ...

gynecologic cancers

Bariatric Surgery May Lower Risk of Uterine Cancer

Women who had bariatric surgery to lose weight had a 70% lower risk of uterine cancer and an even lower risk if they kept the weight off, according to findings presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, held in Tampa, Florida, from March 22 to 25. ...

gynecologic cancers
issues in oncology

FDA Advisory Committee Unanimously Recommends HPV Test as Primary Screening Tool for Detection of Women at High Risk for Cervical Cancer

The U.S. Food and Drug Administration (FDA) Microbiology Devices Panel of the Medical Devices Advisory Committee has recommended unanimously that the benefits of the cobas human papillomavirus (HPV) test outweigh the risks as a first-line primary screening tool to assess the risk of cervical cancer ...

gynecologic cancers
gynecologic cancers

Erlotinib Plus Cisplatin-Based Chemoradiation May Prolong Survival of Patients With Locally Advanced Cervical Cancer

A new clinical study has found that erlotinib (Tarceva) has promising potential to improve treatment for cervical cancer. Published in Cancer, the findings by Nogueira-Rodrigues et al indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for...

gynecologic cancers
pancreatic cancer
solid tumors

Novel Cancer Vaccine Shows Promise in Ovarian Cancer and Mesothelioma

A novel approach to cancer immunotherapy may provide a new and cost-effective strategy against ovarian cancer and mesothelioma. In a study published in the Journal of Hematology & Oncology, Yuan et al reported that a fusion protein engineered to combine a molecule targeting a tumor-cell-surface ...

gynecologic cancers
issues in oncology

Large Study Shows Preventive Ovarian Surgery in BRCA1 Mutation Carriers Should Be Performed Early for Greatest Benefit

The findings of a large international prospective study published in the Journal of Clinical Oncology by Finch et al suggest for the first time that women with BRCA1 mutations should have prophylactic oophorectomy by age 35, as waiting until a later age appears to increase the risk of ovarian...

gynecologic cancers
gynecologic cancers

Recurrent Ovarian Cancers Respond to Cancer Vaccine After ‘Reprogramming’ With Decitabine

Treatment with the drug decitabine prior to administration of chemotherapy and a cancer vaccine yielded clinical benefit for women with recurrent ovarian cancer, suggesting that this combinatorial chemoimmunotherapy may provide a new treatment option for patients with the disease, according to a...

gynecologic cancers
gynecologic cancers

ASTRO: Cisplatin Plus Radiation Therapy for Advanced Cervical Cancer Improves Disease-Free Survival vs Radiotherapy Alone

Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy and high–dose rate brachytherapy for stage IIIB cervical cancer is beneficial, according to research presented on September 22, 2013, at the American Society for Radiation Oncology’s 55th Annual Meeting...

gynecologic cancers

Brachytherapy to Treat Cervical Cancer on the Decline in the United States

A study by researchers at Brigham and Women's Hospital found that brachytherapy was associated with better cause-specific survival and overall survival in women with cervical cancer. The population-based analysis also revealed geographic disparities and decline in brachytherapy treatment in the...

gynecologic cancers
issues in oncology

African American Women Less Likely to Receive HPV Vaccine Than Whites, Study Finds

African American women are less likely to receive the vaccine for human papillomavirus (HPV), even with access to health care, according to a study by researchers at the University of Pittsburgh School of Medicine. The findings, published today in the Journal of Adolescent Health, suggest a need...

gynecologic cancers
issues in oncology

New Screening Strategy May Detect Ovarian Cancer at Early Stages

A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal. The strategy was described in a study published early online this week in Cancer. A clinical trial is ongoing to verify the findings. Karen Lu, MD, of The University of...

gynecologic cancers
head and neck cancer
issues in oncology

HPV Vaccine Reduces Prevalence of Oral HPV Infections in Costa Rican Study

A new study by the International Agency for Research on Cancer (IARC), in partnership with Costa Rican investigators and the National Cancer Institute (NCI), shows for the first time that the vaccine against human papillomavirus (HPV) types 16 and 18, which is used to prevent cervical cancer, also...

Advertisement

Advertisement



Advertisement